GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce lipid accumulation in peripheral tissues, attenuating atherosclerosis and hepatic steatosis in preclinical studies. We examined whether GLP-1R activation decreases atherosclerosis progression in high-fat diet-fed male ApoE(-/-) mice after administration of streptozotocin and treatment with the long-acting GLP-1R agonist taspoglutide administered once monthly vs. metformin in the drinking water for 12 wk. Taspoglutide did not reduce plaque area or lipid content in the aortic arch or abdominal aorta, and no significant change in aortic macrophage accumulation was detected after taspoglutide or metformin. In contrast, hepatic triglyceride levels were significantly reduced in livers from taspoglutide-treated mice. Both peripheral and intracerebroventricular administration of exendin-4 rapidly decreased plasma triglyceride levels in fasted mice, and taspoglutide therapy in ApoE(-/-) mice modulated the expression of hepatic genes controlling fatty acid uptake and oxidation. We were unable to detect expression of the entire Glp1r coding sequence in macrophages isolated from ApoE(-/-), C57BL/6, and IL10(-/-) mice. Similarly, Glp1r mRNA transcripts were not detected in RNA from isolated murine hepatocytes. Using Western blotting and tissue extracts from Glp1r(+/+) and Glp1r(-/-) mice, and cells transfected with a tagged murine GLP-1R cDNA, we could not validate the sensitivity and specificity of three different GLP-1R antisera commonly used for the detection of GLP-1R protein. Taken together, these findings illustrate divergent actions of GLP-1R agonists on atherosclerosis progression and accumulation of ectopic lipid in ApoE(-/-) mice and highlight the importance of indirect GLP-1R actions for the control of hepatic lipid accumulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glp1r expression is undetectable by quantitative PCR in peritoneal or adipose tissue macrophages (37), although Lyz2-Cre–driven deletion of Glp1r (Glp1rLyz2–/–) abolishes expression in bone marrow–derived macrophages (38).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [37]
In the citing paper
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [37]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 2×
“Histological sections were scored for hepatic lobular inflammation, ballooning, apoptosis, Kupffer cells, fibrosis, and steatosis according to guidelines set by the Pathology Committee of the NASH (nonalcoholic steatohepatitis) Clinical Research Network (25) in a blinded manner by a trained pathologist (C.”
Metabolism of Isolated Fat Cells
Rodbell, M. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51687-2 · Cited by 4,427
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Two of the relatively newer classes, glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, exert their glucose-lowering actions predominantly through activation of the GLP-1R (2).”
Self-citationMETABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS.
Rodbell, M. (1964) · PubMed · Cited by 1,387
Insulin Resistance, Hyperglycemia, and Atherosclerosis
Bornfeldt, K. E., & Tabas, I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.015 · Cited by 995 · cited 3×
“Although hyperglycemia and insulin resistance substantially accelerate the development of clinical and experimental atherosclerosis (11), whether sustained activationofGLP-1Rsignalingmightattenuate thedevelopment of atherosclerosis in the setting of insulin resistance, impairment of -cell function, and hyperglycemia r…”
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 6×
“D PBO (14) D Met PBO (15) D TASPO (15) * * ** ***”
InfluentialSelf-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 2×
“In contrast, other investigators have failed to detect mRNA transcripts encoding a full-length Glp1r in human, rat, or mouse liver (17, 37, 47-49), and we previously reported the absence of cAMP accumulation in response to GLP-1 or exendin-4 in isolated murine hepatocytes (17).”
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“ocytes and exert direct effects in the cardiovascular system (3).”
Self-citation
Cited by
Items 201–300 of 346
Nakashima, K., Kaneto, H., Shimoda, M., Kimura, T., & Kaku, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-21751-w · Cited by 32
Chen, L., Fang, Z., Wang, X., Sun, X., Ge, X., Cheng, C., & Hu, H. (2021) · Bioengineered · doi:10.1080/21655979.2021.1952917 · Cited by 28
“Lipid accumulation is known to be a part of the progress of atherosclerosis [21].”
BackgroundPleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 32
Sassoon, D., Goodwill, A. G., Noblet, J. N., Conteh, A. M., Herring, B. P., McClintick, J. N., Tune, J. D., & Mather, K. J. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0563-4 · Cited by 28
“These observations contribute to the growing body of experimental and clinical literature supporting marked differences in cardiovascular responses to GLP-1 therapeutics in the setting of obesity [20, 44, 46, 64].”
Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism
Batran, R. A., Almutairi, M. G., & Ussher, J. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.005 · Cited by 29
Lee, Y. S., Riopel, M., Cabrales, P., & Bandyopadhyay, G. K. (2019) · Science Advances · doi:10.1126/sciadv.aaw4176 · Cited by 33
Patel, V., Joharapurkar, A., Kshirsagar, S., Sutariya, B., Patel, M., Pandey, D., Patel, H., Ranvir, R., Kadam, S., Patel, D., et al. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.01.004 · Cited by 27
Gejl, M., Rungby, J., Brock, B., & Gjedde, A. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12240 · Cited by 27
Qa’aty, N., Wang, Y., Wang, A., Mao, S., Vincent, M. L., Husain, M., & Hinek, A. (2014) · Endocrinology · doi:10.1210/en.2014-1519 · Cited by 27
Koshibu, M., Mori, Y., Saito, T., Kushima, H., Hiromura, M., Terasaki, M., Takada, M., Fukui, T., & Hirano, T. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00511.2018 · Cited by 27
Kang, Z., Zeng, J., Zhang, T., Lin, S., Gao, J., Jiang, C., Fan, R., & Yin, D. (2019) · Cell Biology International · doi:10.1002/cbin.11184 · Cited by 32
“High glucose conditions decreased GLP‐1R signal pathways in HBZY‐1 cells and in kidneys from db/db diabetic mice Because of sensitivity or specificity, the commercial GLP‐1R antibody does not correctly display GLP‐1R expression by immunoblotting (Panjwani et al., 2013).”
Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
Inia, J. A., Stokman, G., Morrison, M. C., Worms, N., Verschuren, L., Caspers, M. P. M., Menke, A. L., Petitjean, L., Chen, L., Petitjean, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108494 · Cited by 33
“to be due to a lack of sensitivity and specificity of three commercially available GLP-1 receptor antibodies [45].”
BackgroundPetta, S., Kim, K., Targher, G., Romeo, S., Sookoian, S. C., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70407 · Cited by 36
Bariatric surgery and nonalcoholic fatty liver disease
Bower, G., Athanasiou, T., Martínez-Isla, A., Harling, L., Li, J. V., Holmes, E. C., Efthimiou, E., Darzi, A. W., & Ashrafian, H. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000375 · Cited by 30
Natalicchio, A., Biondi, G., Marrano, N., Labarbuta, R., Tortosa, F., Spagnuolo, R., D’Oria, R., Carchia, E., Leonardini, A., Cignarelli, A., et al. (2016) · Endocrinology · doi:10.1210/en.2015-2003 · Cited by 32
Sex-Specific Effect of High-Fat Diet on Glycerol Metabolism in Murine Adipose Tissue and Liver
Iena, F. M., Jul, J. B., Vegger, J. B., Lodberg, A., Thomsen, J. S., Brüel, A., & Lebeck, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.577650 · Cited by 31
“However, AQP7 is in AT predominantly expressed in endothelial cells (22) and GLP-1R mRNA has been shown in the stromal vascular fraction from AT (33), and GLP1R abundance has been reported in renal endothelial cells (34).”
BackgroundResultNovel extrapancreatic effects of incretin
Yamada, Y., Tsukiyama, K., Sato, T. K., Shimizu, T., Fujita, H., & Narita, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12495 · Cited by 27
“GLP-1 (7-37) and GLP-1(7-36) amide were shown to be released from intestinal L cells, and stimulate insulin secretion from pancreatic b-cells directly(6).”
BackgroundKawaguchi, T., Itou, M., Taniguchi, E., & Sata, M. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1826 · Cited by 24
“…studies have also shown that reduced hepatic accumulation of triglycerides is mediated by GLP-1R agonist upregulation of hepatic 3-phosphoinositide-dependent kinase-1 activity, protein kinase C ζ activity, peroxisome proliferator-activated receptor α activity, and fatty acid β -oxidation (15-19).”
Influence of GLP-1 on Myocardial Glucose Metabolism in Healthy Men during Normo- or Hypoglycemia
Gejl, M., Lerche, S. S., Mengel, A., Møller, N., Bibby, B. M., Smidt, K., Brock, B., Søndergaard, H. M., Bøtker, H. E., GJEDDE, A. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083758 · Cited by 26
Ando, H., Ushijima, K., & Fujimura, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081119 · Cited by 25
“recently showed that both mRNA and protein levels of the GLP-1 receptor are undetectable in mouse hepatocytes [40].”
BackgroundYu, P., Xu, X., Zhang, J., Xia, X., Xu, F. L., Weng, J., Lai, X., & Shen, Y. (2019) · International Journal of Endocrinology · doi:10.1155/2019/1567095 · Cited by 26
Younce, C. W., Niu, J., Ayala, J., Burmeister, M. A., Smith, L. H., Kolattukudy, P. E., & Ayala, J. E. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.08.022 · Cited by 26
“However, it is unclear whether Glp1r agonists directly target macrophages since a recent report suggests that the Glp1r is not expressed in these cells [12].”
Bangshaab, M., Cruz, A. G., Huynh, K. D., Knudsen, J. S., Arcanjo, D. D. R., Petersen, A. G., Rungby, J., Gejl, M., & Simonsen, U. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14534 · Cited by 27
“However, some papers have questioned data obtained using standard antisera to detect GLP-1 receptors (Pyke and Knudsen, 2013; Panjwani et al., 2012).”
BackgroundLi, X., Wu, X., Jia, Y., Fu, J., Zhang, L., Jiang, T., Liu, J., & Wang, G. (2021) · Journal of Diabetes Research · doi:10.1155/2021/3715026 · Cited by 26
“Panjwani and colleagues have showed that previous observations showing the detection of GLP-1R in human and mouse liver are likely due to the lack of reliable antibody [28, 29].”
BackgroundMiao, L., Xu, J., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0015 · Cited by 27
Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6
Li, R., Ye, Z., She, D., Fang, P., Zong, G., Hu, K., Kong, D., Xu, W., Li, L., Zhou, Y., et al. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s384884 · Cited by 24
“38 Our study validated the mRNA and protein expression of GLP-1R in liver tissue and in hepatocytes.”
BackgroundCombined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
Ying, Z., van Eenige, R., Ge, X., van Marwijk, C., Lambooij, J. M., Guigas, B., Giera, M. A., de Boer, J. F., Coşkun, T., Qu, H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104684 · Cited by 28
Burghi, V., Fernández, N. C., Gándola, Y. B., Piazza, V. G., Quiroga, D. T., Mário, É. G., Braga, J. F., Bäder, M., Santos, R. A. S., Dominici, F. P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183278 · Cited by 26
Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo
Ast, J., Novak, A. N., Podewin, T., Fine, N. H. F., Jones, B. J., Tomás, A., Birke, R., Roßmann, K., Mathes, B., Eichhorst, J., et al. (2022) · JACS Au · doi:10.1021/jacsau.2c00130 · Cited by 25
Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
HOFFMAN, S. S., & Adeli, K. (2024) · Medical Review · doi:10.1515/mr-2024-0011 · Cited by 26
“Consequently, con fl icting evidence exists regarding the presence of GLP-1Rs on hepatocytes [53 – 56].”
BackgroundAnti-diabetic drugs and NASH: from current options to promising perspectives
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 22
Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
Padda, J., Khalid, K., Khedr, A., Tasnim, F., Al-Ewaidat, O. A., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.17321 · Cited by 29
“However, whether human hepatocytes have GLP-1 receptors or how GLP-1 agonists act on the liver is still not clear [99-102].”
BackgroundKatsuda, Y., Ohta, T., Shinohara, M., Tong, B., & Yamada, T. (2013) · Open Journal of Animal Sciences · doi:10.4236/ojas.2013.34050 · Cited by 27
Nielsen, M. H., Nøhr-Meldgaard, J., Møllerhøj, M. B., Oró, D., Pors, S. E., Andersen, M. W., Kamzolas, I., Petsalaki, E., Vacca, M., Harder, L. M., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2024 · Cited by 21
Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice
Liu, D., Gu, J., Shao, W., Pang, J., Qian, X., & Jin, T. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.08.012 · Cited by 22
The Molecular Determinants of Glucagon-like Peptide Secretion by the Intestinal L cell
Brubaker, P. L. (2022) · Endocrinology · doi:10.1210/endocr/bqac159 · Cited by 23
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
“visceral adipose tissue, as well as in preadipocytes and differentiated adipocytes ex vivo, detection of the GLP-1R with commercially available antisera has been problematic (55, 56),”
BackgroundSelf-citationLi, W., Kirchner, T., Ho, G., Bonilla, F., D'Aquino, K., Littrell, J., Zhang, R., Jian, W., Qiu, X., Zheng, S., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14173 · Cited by 20
Sato, H., Kubota, N., Kubota, T., Takamoto, I., Iwayama, K., Tokuyama, K., Moroi, M., Sugi, K., Nakaya, K., Goto, M., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4071-8 · Cited by 19
Valdecantos, M. P., Ruíz-Cañas, L., Pardo, V., Castro‐Sánchez, L., García‐Monzón, C., Lanzón, B., Rupérez, F. J., Barbas, C., Naylor, J., Trevaskis, J. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33949-z · Cited by 20
GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions
Li, H., Donelan, W., Wang, F., Zhang, P., Yang, L., Ding, Y., Tang, D., & Li, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.777026 · Cited by 21
“On the other hand, RNA-seq, in situ hybridization, or GLP-1R antisera analysis showed no to low expression of GLP-1R in hepatocytes, skeletal myocytes, and adipocytes (Campbell and Drucker, 2013; Panjwani et al., 2013).”
BackgroundScavo, M. P., Lisco, G., Depalo, N., Rizzi, F. R., Volpe, S., Arrè, V., Carrieri, L., Notarnicola, M., Nunzio, V. D., Curri, M. L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031493 · Cited by 19
Iwamoto, Y., Kimura, T., Dan, K., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Shimoda, M., Yamasaki, Y., Nogami, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15972 · Cited by 22
Pan, X., Xu, S., Li, J., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.599355 · Cited by 21
Snook, L. A., Nelson, E. M., Dyck, D. J., Wright, D. C., & Holloway, G. P. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00003.2015 · Cited by 17
Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
de Bray, A., Roberts, A. G., Armour, S. L., Tong, J., Huhn, C., Gatin‐Fraudet, B., Roßmann, K., Shilleh, A. H., Jiang, W., Burgos, N. S. F., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01342-6 · Cited by 21
“No approach to date provides information on GLP1Rs and GIPRs specifically accessed or bound by a dual agonist.”
Orphan GPR146: an alternative therapeutic pathway to achieve cholesterol homeostasis?
Wilkins, B. P., Finch, A. M., Wang, Y., & Smith, N. J. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.04.008 · Cited by 19
Cardiovascular and hemodynamic effects of glucagon-like peptide-1
Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D. J., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 17
“Data from our laboratory and others suggest that obesity and diabetes impair the beneficial effects of GLP-1 treatments in the heart, with the clear implication that the population who will most commonly be treated with GLP-1 related agents may not accrue the anticipated metabolic and anti-ischemic benefits [33, 66, 7…”
Lehtonen, J., Schäffer, L., Rasch, M. G., Hecksher-Sørensen, J., & Ahnfelt-Rønne, J. (2015) · Islets · doi:10.1080/19382014.2015.1137415 · Cited by 17
Shantaram, D., Rima, X. Y., Bradley, D. P., Liu, J. Z., Wright, V. P., AMARI, A., Jalilvand, A., Rottinghaus, J., Fernandes, J. M., Smith, A. J., et al. (2025) · Diabetes · doi:10.2337/db24-0861 · Cited by 18
Njei, B. M., Al‐Ajlouni, Y. A., Lemos, S. Y., Ugwendum, D. F., Ameyaw, P. A., Njei, L., & Boateng, S. (2024) · Cureus · doi:10.7759/cureus.71366 · Cited by 30
Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
Makino, Y., Fujita, Y., & Haneda, M. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000080 · Cited by 18
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“However, the presence of these receptors in hepatocytes and their exact localisation in the liver remains a subject of debate [64].”
GABA requires GLP-1R to exert its pancreatic function during STZ challenge
Shao, W., Liu, W., Liang, P., Song, Z., Israel, O., Prud’homme, G. J., Wang, Q., & Jin, T. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0109 · Cited by 15
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
Hansen, J., Brock, B., Bøtker, H. E., GJEDDE, A. H., Rungby, J., & Gejl, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9286-8 · Cited by 16
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
Zhong, J., Maiseyeu, A., & Rajagopalan, S. (2015) · Clinical Lipidology · doi:10.2217/clp.14.59 · Cited by 16
Feng, J. N., Shao, W., & Jin, T. (2023) · Physiological Reports · doi:10.14814/phy2.15620 · Cited by 14
Rai, C., & G., P. P. C. (2023) · European Journal of Nutrition · doi:10.1007/s00394-023-03162-4 · Cited by 15
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
Feng, J. N., & Jin, T. (2024) · Medical Review · doi:10.1515/mr-2024-0018 · Cited by 18
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Patel, K. N., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2015) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0457 · Cited by 15
“It is observed that sustained peripheral GLP-1R activation increased hepatic lipid oxidation, reduced lipogenesis, and decreased lipoprotein secretion from liver (Ding et al. 2006; Panjwani et al. 2013; Parlevliet et al. 2010), whereas acute i.”
BackgroundhESCs‐derived Organoids Achieve Liver Zonation Features through LSEC Modulation
Zhang, Y., Huang, C., Sun, L., Zhou, L., Niu, Y., Liang, K., Wu, B., Zhao, P., Liu, Z.-Q., Zhou, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202411667 · Cited by 20
Roy, D., Chadwick, K. D., Tatarkiewicz, K., LaCerte, C., Bergholm, A., Brodie, T., Mangipudy, R. S., Parkes, D. G., Graziano, M. J., & Reilly, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12294 · Cited by 13
“However, it was recently reported that the current antisera commercially available for detection of GLP-1 receptor expression and gene expression quantification in exocrine and endocrine pancreatic tissues are severely lacking in both specificity and sensitivity [79,80].”
BackgroundTsiampali, C., Vachliotis, I. D., Goulas, A., & Pοlyzos, S. A. (2024) · HORMONES · doi:10.1007/s42000-024-00541-2 · Cited by 13
“Some authors have supported the presence of GLP-1 receptors on the hepatocytes [54], while others do not [55].”
BackgroundIncretins and bone: friend or foe?
Mabilleau, G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.007 · Cited by 14
Ståhle, M. R., Hellberg, S., Virta, J., Liljenbäck, H., Metsälä, O., Li, X., Jauhiainen, M., Saukko, P. J., Ylä‐Herttuala, S., Nuutila, P., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00465.2020 · Cited by 13
Morieri, M. L., Targher, G., Lapolla, A., D'Ambrosio, M., Tadiotto, F., Rigato, M., Frison, V., Paccagnella, A., Simioni, N., Avogaro, A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.049 · Cited by 15
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
Wong, C. K., Yusta, B., Tong, J. C. L., Broichhagen, J., Hodson, D. J., & Drucker, D. J. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.012 · Cited by 14
Self-citationWu, L., An, R., Lan, T., Tang, Z., Xu, Y., Peng, X., Pang, J., Sun, W., Shi, B., Tang, Q., et al. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109534 · Cited by 12
Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
Solun, B., Marcoviciu, D., & Dicker, D. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0382-2 · Cited by 12
Tissue-Specific Expression of GLP1R in Mice: Is the Problem of Antibody Nonspecificity Solved?
Aroor, A. R., & Nistala, R. (2014) · Diabetes · doi:10.2337/db13-1937 · Cited by 11
“So far, this has been elusive due to the paucity of “good” antibodies against GLP1R that produce accurate, reliable, and reproducible data (1,2).”
BackgroundGuo, J., Pereira, T. J., Dalvi, P. S., Yeung, L. S. N., Swain, N., Breen, D. M., Lam, L., Dolinsky, V. W., & Giacca, A. (2016) · Metabolism · doi:10.1016/j.metabol.2016.12.002 · Cited by 13
Eda, H., Fukui, H., Uchiyama, R., Kitayama, Y., Hara, K., Yang, M., Kodani, M., Tomita, T., Oshima, T., Watari, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177232 · Cited by 12
Virta, J., Hellberg, S., Liljenbäck, H., Ståhle, M. R., Silvola, J. M. U., Huusko, J., Söderström, M., Knuuti, J. M., Nuutila, P., Ylä‐Herttuala, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.029 · Cited by 10
Synthesis and Evaluation of Optical and PET GLP-1 Peptide Analogues for GLP-1R Imaging
Azad, B. B., Rota, V., Yu, L., McGirr, R., Amant, A. H. S., Lee, T.-Y., Dhanvantari, S., & Luyt, L. G. (2015) · Molecular Imaging · doi:10.2310/7290.2014.00057 · Cited by 10
“labeled GLP-1(7-37) peptides in CD1 and C57BL/6 mice.”
BackgroundMethodBrain Control of Plasma Cholesterol Involves Polysialic Acid Molecules in the Hypothalamus
Brénachot, X., Gautier, T., Nédélec, E., Deckert, V., Laderrière, A., Nuzzaci, D., Rigault, C., Lemoine, A., Pénicaud, L., Lagrost, L., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00245 · Cited by 9
“, 2016), and Glp-1 (Parlevliet et al., 2012; Panjwani et al., 2013; Taher et al., 2014), trigger brainmediated regulation of hepatic cholesterol metabolism.”
Itoh, A., Irie, J., Tagawa, H., Kusumoto, Y., Kato, M., Kobayashi, N., Tanaka, K., Kikuchi, R., Fujita, M., Nakajima, Y., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.05.013 · Cited by 13
GLP-1 and IL-6 regulates obesity in the gut and brain
Yang, K., Wu, Y., He, Y., Dai, J.-X., Luo, Y.-L., Xie, J.-H., & Ding, W. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123339 · Cited by 8
Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue
Gu, J., Shao, W., Liu, D., Feng, J. N., Pang, J., & Jin, T. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0026 · Cited by 8
Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues
Molin, M. D., Kim, H., Blackford, A. L., Sharma, R. B., & Goggins, M. (2015) · Pancreas · doi:10.1097/mpa.0000000000000521 · Cited by 10
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Tsiampali, C., Papaioannidou, P., Goulas, A., & Pοlyzos, S. A. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274536 · Cited by 10
Tajima, K., Shirakawa, J., Togashi, Y., Inoue, H., Sato, K., Orime, K., Ito, Y., Kaji, M., Sakamoto, E., Nakamura, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064633 · Cited by 8
Control of liver glucokinase activity: A potential new target for incretin hormones?
Francini, F., Massa, M. L., Polo, M. P., Villagarcía, H. G., Castro, M. C., & Gagliardino, J. J. (2015) · Peptides · doi:10.1016/j.peptides.2015.10.006 · Cited by 7
van Eyk, H. J., Blauw, L. L., Bizino, M. B., Wang, Y., van Dijk, K. W., de Mutsert, R., Smit, J. W. A., Lamb, H. J., Jazet, I. M., & Rensen, P. C. N. (2019) · Scientific Reports · doi:10.1038/s41598-019-45593-2 · Cited by 7
Li, C., Zhao, L., Zhou, X., Wu, H., & Zhao, J. (2015) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-015-1433-2 · Cited by 8
Acute Cholesterol-Lowering Effect of Exendin-4 in Ldlr−/− and C57BL/6J Mice
Hori, M., Hasegawa, Y., Hayashi, Y., Nakagami, T., & Harada‐Shiba, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60921 · Cited by 8
Incretin Hormones in the Control of Immunometabolism
Fishman, S., Zvibel, I., & Varol, C. (2019) · Immunometabolism · doi:10.20900/immunometab20190004 · Cited by 6
“However, determination of cells expressing a functional GLP-1R or GIPR remains so far challenging mainly due to the uncertain sensitivity and specificity of commonly used antisera [90].”
BackgroundHydrogel Microparticle Encapsulation Enhances In Vivo Peptide Delivery of Recombinant Probiotics
Gao, S., Liang, K., Fan, Z., Ao, Y., Liu, W., Li, W., Zhang, Y., & Du, Y. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202412859 · Cited by 5
GPCR Promiscuity Reshapes Islet Physiology
Schuit, F. C., & Campbell, J. E. (2023) · Diabetes · doi:10.2337/dbi23-0014 · Cited by 5
Self-citationGLP-1R signaling does not modify the severity of experimental graft versus host disease
Yusta, B., Wong, C. K., Matthews, D., Koehler, J. A., Baggio, L. L., Bang, K. W. A., & Drucker, D. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102235 · Cited by 7
“The resulting cDNA was used for both conventional and for real-time qPCR. PCR amplification of the murine Glp1r was accomplished as described [34] using Platinum Taq DNA polymerase and primers that amplify a 1.4-kb product encompassing the majority of the Glp1r open reading frame.”
InfluentialSelf-citationStarup‐Linde, J. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000389 · Cited by 4
“Prior studies have demonstrated the presence of GLP-1 receptors in the myocardium [22,23], but recent papers [24-26] have questioned the interpretation of data obtained using commercially available GLP-1 antisera to detect the authentic GLP-1 receptor.”
ResultThe role of GLP-1 receptor in pain disorders and its pharmacological properties
Jing, F., Zeng, Y., Yu, Q.-L., & Fu, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178345 · Cited by 6
Musso, G., Pinach, S., Cassader, M., Mariano, F., & Gambino, R. (2026) · Med · doi:10.1016/j.medj.2025.100959 · Cited by 4
The role of PYY in improving insulin resistance
Liu, C., Na, R., Zhang, H., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1784709 · Cited by 6
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
Trusca, V. G., Fuior, E. V., & Gafencu, A. V. (2015) · Current Molecular Medicine · doi:10.2174/1566524016666151123110310 · Cited by 4
Eisenstein, E. L., Peterson, E. D., Jollis, J. G., Tardiff, B. E., Califf, R. M., Knight, J. D., & Mark, D. B. (1997) · Europe PMC (PubMed Central) · Cited by 5
Mermet, M., Denom, J., Mieczkowska, A., Wery, M., Biggs, E. K., Gribble, F. M., Reimann, F., Magnan, C., Cruciani‐Guglielmacci, C., & Mabilleau, G. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00086.2025 · Cited by 8
“However, it should be noted that no commercially available antibody specific to the murine GLP-1r exists, and several researchers, including ourselves, have previously reported this issue (24, 25).”
Supaglutide alleviates hepatic steatosis in monkeys with spontaneous MASH
Wang, Q., Zhou, Y., Ni, Y., Wang, Z., Lou, Y.-R., Yang, Z., Gong, L., Liang, Y., Zeng, W., & Prud’homme, G. J. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01513-7 · Cited by 4
Peart, L. A., Draper, M., & Tarasov, A. I. (2024) · Peptides · doi:10.1016/j.peptides.2024.171243 · Cited by 5
A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
Junker, A. E., Gluud, L. L., Pedersen, J., Langhoff, J. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2014) · Case Reports in Gastroenterology · doi:10.1159/000369968 · Cited by 4
Metadata
- Authors
- Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 154
- Issue
- 1
- Pages
- 127-139
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1992116679
- Cited by
- 346
- References
- 53
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 19 · 2023: 23 · 2022: 23 · 2021: 21 · 2020: 24 · 2019: 23 · 2018: 27 · 2017: 24 · 2016: 26 · 2015: 32 · 2014: 38 · 2013: 32
- FWCI
- 26.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- GLP-1 receptor, exendin-4, atherosclerosis, hepatic lipid accumulation, hepatic steatosis, ApoE-deficient mice, streptozotocin-induced diabetes, metformin, aortic plaque, hepatic triglycerides, fatty acid uptake, fatty acid oxidation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Apolipoproteins E, Body Composition, Glucose Tolerance Test, Liver, Macrophages, Male, Peptides, Blotting, Western, Interleukin-10, Receptors, Glucagon, Mice, Knockout, Hepatocytes, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.